PMID- 11084114
OWN - NLM
STAT- MEDLINE
DCOM- 20051220
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 86
IP  - 9A
DP  - 2000 Nov 2
TI  - Pacing Therapies in Congestive Heart Failure II study.
PG  - 138K-143K
AB  - Ventricular resynchronization therapy (VRT) by left or biventricular stimulation 
      is gaining increasing acceptance as a new therapy in addition to drugs in 
      patients with advanced heart failure and intraventricular conduction 
      disturbances. Several studies have demonstrated acute hemodynamic benefit of VRT 
      in these patients, although there are only limited long-term data in small 
      patient cohorts. Many open questions remain: whether to pace both ventricles or 
      the left ventricle alone, the optimal left ventricular pacing site, the criteria 
      used to identify the optimal candidate for VRT (e.g., QRS width), and the 
      importance of an integrated defibrillator function in a VRT device. The Pacing 
      Therapy in Congestive Heart Failure (PATH-CHF) II study is a prospective, 
      randomized, cross-over study currently investigating the potential benefit of VRT 
      in a population with advanced heart failure, with or without an accepted 
      indication for an implantable defibrillator. It focuses on the effects of 
      optimized univentricular pacing in these patients, and both acute hemodynamic and 
      chronic functional effects are assessed. Acute hemodynamic testing mainly 
      investigates the impact of different left ventricular pacing sites, alone or 
      combined with right ventricular sites, on hemodynamic performance. Primary 
      endpoint of the study is an improvement in functional capacity as assessed by 
      cardiopulmonary exercise testing and 6-minute walk distance; secondary endpoints 
      include improvement in quality of life (assessed by Minnesota quality of life 
      score, New York Heart Association (NYHA) functional class, and hospitalization 
      frequency), and improvements in prognostic and hemodynamic parameters. The trial 
      aims to enroll 64 patients with full datum sets (separately in 2 groups with a 
      QRS of < or = 150 or > 150 msec, respectively) in 9 European centers. The 
      enrollment began September 1998, and is expected to conclude in summer 2000 to 
      reach the number of necessary datum sets.
FAU - Stellbrink, C
AU  - Stellbrink C
AD  - University Hospital RWTH, Aachen, Germany.
FAU - Auricchio, A
AU  - Auricchio A
FAU - Butter, C
AU  - Butter C
FAU - Sack, S
AU  - Sack S
FAU - Vogt, J
AU  - Vogt J
FAU - Bocker, D
AU  - Bocker D
FAU - Block, M
AU  - Block M
FAU - Kirkels, H
AU  - Kirkels H
FAU - Ramdat-Misier, A
AU  - Ramdat-Misier A
CN  - PATH-CHF II Study Group
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
SB  - IM
MH  - Arrhythmias, Cardiac/etiology/*therapy
MH  - Cardiac Pacing, Artificial/*methods
MH  - Cross-Over Studies
MH  - Heart Failure/*complications
MH  - Hemodynamics
MH  - Humans
MH  - Patient Selection
MH  - Prospective Studies
MH  - Research Design
EDAT- 2000/11/21 00:00
MHDA- 2005/12/21 09:00
CRDT- 2000/11/21 00:00
PHST- 2000/11/21 00:00 [pubmed]
PHST- 2005/12/21 09:00 [medline]
PHST- 2000/11/21 00:00 [entrez]
AID - S0002914900012984 [pii]
AID - 10.1016/s0002-9149(00)01298-4 [doi]
PST - ppublish
SO  - Am J Cardiol. 2000 Nov 2;86(9A):138K-143K. doi: 10.1016/s0002-9149(00)01298-4.